Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at tracy@fiercemarkets.com or find her on LinkedIn.

Articles by Tracy Staton

Why do vaccines cost so much? Ask Pfizer about Prevnar 13

We're accustomed to the fact that U.S. payers shell out more for drugs and vaccines than payers in other countries that have cost-conscious government gatekeepers. But a new analysis by The New York Times shows that, in the vaccines market, pricing is even more schizophrenic than that.

Zogenix puts Zohydro 2.0 into high gear, aiming to beat Purdue, Teva

Zogenix knows it needs to step on the gas. If the company doesn't develop an abuse-resistant version of its controversial-and-powerful painkiller Zohydro--and quickly--another drugmaker will speed past.

Rottapharm founders price IPO valuing company at up to $2.46 billion

Two years ago, Rottapharm's founding family gave up on selling a big stake in the company. Word was, the offers didn't quite measure up to the asking price--and the Rovati family wanted to keep more power than buyers were willing to give. Now, the Italian drugmaker is planning an IPO that would value the company at €1.45 billion to €1.8 billion, or up to $2.46 billion.

Not for sale, says new Actavis CEO. We're buying instead

After serving as Bausch & Lomb's chief exec for just 5 months, incoming Actavis CEO Brent Saunders wants to keep his new job for awhile. So forget selling the company, fast-growing and attractive as it may be, Saunders is more interested in buying.

Amgen scores FDA's 'breakthrough' nod for prospective leukemia therapy

Amgen nabbed a breakthrough designation for its mid-stage blood cancer drug blinatumomab.

Apparently confident AstraZeneca CEO socks $3.4M into company shares

Pascal Soriot has raised the stakes on AstraZeneca's turnaround. The chief executive plunked down $3.4 million to buy more of his company's shares. 

New highest-paid CEO: United Therapeutics chief collected $38M in 2013

A few weeks ago, we published our annual list of highest-paid biopharma CEOs. Now, we're saying whoops! Sitting at the top of our list was Regeneron CEO Leonard Schleifer with $36.27 million in 2013 compensation. But United Therapeutics chief Martine Rothblatt should have had that spot.

Wanted: Marketing strategy for MannKind's long-time-coming inhaled insulin

MannKind's third-time's-the-charm win on its inhaled insulin Afrezza isn't the finish line for the long-suffering company.

Sex, bribes and videotape: Clandestine video of GSK exec adds to China scandal

Last year, as the GlaxoSmithKline bribery probe was heating up, a British P.I. and his wife appeared on Chinese television, wearing handcuffs and prison orange. Word was, their sleuthing firm, ChinaWhys, had been working for pharma companies. Their alleged crime: collecting private information on Chinese citizens.

Republicans back generic industry's fight against FDA labeling rule

Two Republican lawmakers are supporting the generic industry's fight against the FDA's proposed rule on product labeling.